Last reviewed · How we verify
Adenocarcinoma of the ovary — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cytoxan (Lyophilized) | cyclophosphamide | Baxter | Alkylating agent | Tumor cell DNA | 1959-01-01 | |
| Cyclophosphamid | Cyclophosphamid | Zhejiang University | Cytochrome P450 3A4 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Baxter · 2 drugs in Adenocarcinoma of the ovary
- Zhejiang University · 1 drug in Adenocarcinoma of the ovary
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Adenocarcinoma of the ovary:
- Adenocarcinoma of the ovary treatment updates — RSS
- Adenocarcinoma of the ovary treatment updates — Atom
- Adenocarcinoma of the ovary treatment updates — JSON
Cite this brief
Drug Landscape (2026). Adenocarcinoma of the ovary — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adenocarcinoma-of-the-ovary. Accessed 2026-06-11.
Related
- Adenocarcinoma of the ovary full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing